Narrative Intelligence · Updated August 2, 2026
JNJ
Narrative intelligence report
Healthcare · PHARMACEUTICAL PREPARATIONS
$255.82
 
Bullish narrative Whale Accumulation Overvalued Stable

JNJ Stock — Narrative & Sentiment Analysis

What the market believes about JNJ right now — a forensic read of the story, not a buy or sell rating.
Market Prism verdictOvervalued Stable

The short answer: JNJ looks overvalued but stable — the move is fragile and worth watching closely. Narrative energy is cooling at 50%.

Live price Updated August 2, 2026 Proprietary forensic signals

JNJ looks overvalued but stable, trading 82.3% above estimated fair value. The story driving JNJ right now: Johnson & Johnson's stock showed identifiable indicators that predicted its recent surge. High volatility-momentum readings (100) indicate significant narrative-driven price displacement.

Reality vs. Belief

How far JNJ's narrative has drifted from its fundamentals.
REALITYBELIEF
Plausible zone
30/100

JNJ's narrative runs slightly ahead of its fundamentals, but stays within a defensible range.

Driving theme Earnings Season
Signal Lab — last 7 days
7D
Narrative Force Risk Pressure

Key signals

Valuation gap
+82.3%
Above narrative fair value
Narrative persistence
80
Very Persistent
Narrative half-life
22.7d
Attention decay
Source credibility
84
Highly Credible
Coordination
30
Organic Spread
Signal reliability
80
Highly Reliable

What's driving JNJ right now

The story driving JNJ right now: Johnson & Johnson's stock showed identifiable indicators that predicted its recent surge. High volatility-momentum readings (100) indicate significant narrative-driven price displacement.

Is JNJ overvalued?

JNJ is trading 82.3% above its estimated fair value, a level that flags significant overvaluation risk.

What happens next for JNJ

Overvalued-but-stable names can hold a premium for a while. The risk is asymmetric: limited upside, with a long way to fall if the story cracks. The 82.3% fair-value deviation is extreme and, historically, tends to revert within 30–60 trading days.

Projected price & trade signal

🔒 Members only
See JNJ's projected price & full trade signal
Fair value, projected targets, direction, and conviction are part of the full JNJ analysis.
Unlock full analysis → Already a member? Sign in

Frequently asked questions

Why is JNJ stock moving today?

The story driving JNJ right now: Johnson & Johnson's stock showed identifiable indicators that predicted its recent surge. High volatility-momentum readings (100) indicate significant narrative-driven price displacement.

Is JNJ overvalued right now?

JNJ is trading 82.3% above its estimated fair value, a level that flags significant overvaluation risk.

What is Market Prism's verdict on JNJ?

Market Prism classifies JNJ as Overvalued Stable — the price sits above what the narrative justifies, but the story isn't actively breaking down. Narrative energy is moderating at 50%, an early sign of fatigue.

What happens next for JNJ?

Overvalued-but-stable names can hold a premium for a while. The risk is asymmetric: limited upside, with a long way to fall if the story cracks. The 82.3% fair-value deviation is extreme and, historically, tends to revert within 30–60 trading days.

Should I buy JNJ stock?

Market Prism does not provide buy or sell recommendations. Our forensic analysis shows: JNJ looks overvalued but stable, trading 82.3% above estimated fair value. Investors should use this signal intelligence alongside their own due diligence and professional financial advice.

The full picture on JNJ — updated every day.

Market Prism reverse-engineers the story behind JNJ's price: fair value, narrative energy, coordination, and the projected trade signal. Real-time, forensic, and impossible to get from a chatbot.

Market Prism provides forensic narrative intelligence for informational purposes only. This is not financial advice. Projected values reflect narrative-implied modeling, not price predictions, and may be incomplete or unavailable for some tickers. See our methodology. All investment decisions should be made with independent verification and professional financial counsel.